Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional) | PAR 21 319

Frequently Asked Questions (FAQs)

What is PAR-21-319 (Global Brain and Nervous System Disorders Research Across the Lifespan)?

PAR-21-319 is a National Institutes of Health (NIH) funding opportunity that uses the R21 (exploratory and developmental) grant mechanism to support early, innovative research on brain and broader nervous system function, development, and disorders across the lifespan, with an emphasis on global relevance.

What type of NIH grant mechanism is this?

This opportunity uses the R21 mechanism, which is designed to spark new ideas, support feasibility testing, and generate proof-of-concept or preliminary data that can later support larger, more comprehensive research programs.

What does "Clinical Trial Optional" mean for this FOA?

"Clinical Trial Optional" means your project may include a clinical trial if it fits the scientific aims, but a clinical trial is not required. Non-trial studies (such as observational, mechanistic, methodological, public health, or implementation-focused work) can also be proposed.

What is the main focus or theme of this opportunity?

The central theme is research that is globally relevant, with a clear emphasis on questions that matter in low- and middle-income countries (LMICs), where the burden of neurological, mental, behavioral, alcohol, and substance use disorders can be high and where research funding and infrastructure may be limited.

What kinds of research topics are within scope?

The scope is intentionally broad and can include projects anywhere along the research pipeline, from basic and mechanistic science to clinical research, public health research, and implementation research, as long as the focus relates to brain and nervous system function, development, and disorders across the lifespan.

Does the FOA allow research across different stages of life?

Yes. The FOA explicitly supports research across all stages of life, including early childhood and neurodevelopment, adolescent mental health and substance use risk, adult neurological and psychiatric disorders, and aging-related neurodegeneration and cognitive decline.

Is this opportunity limited to neuroscience only?

It is centered on brain and broader nervous system function and disorders, and it recognizes high-burden conditions that can include neurological, mental, behavioral, alcohol, and substance use disorders, particularly in LMIC settings.

What outcomes or impacts is NIH looking for from supported projects?

Supported projects are expected to help generate scientific insight and locally grounded evidence that could contribute to better diagnostics, prevention strategies, treatments, and practical implementation approaches that fit real-world LMIC settings. NIH also signals value in strengthening longer-term research ecosystems and partnerships in participating countries.

How important is collaboration for this program?

Collaboration is a defining feature. The program is designed to spark new, innovative research collaborations and emphasizes building sustainable research capacity in LMICs through durable partnerships and research networking.

Who can partner with LMIC institutions under this FOA?

Investigators based in the United States or in upper-middle income countries (UMICs) are eligible to partner with scientists at LMIC institutions. Scientists in UMICs may also partner directly with other LMIC institutions, with or without a U.S. collaborator.

How are LMIC and UMIC categories determined?

The program relies on World Bank country income classifications to define LMIC and UMIC categories, providing a consistent basis for eligibility determinations.

Is capacity building in LMICs part of the program expectations?

Yes. Beyond the specific research results, NIH indicates that it values projects that help build longer-term LMIC research capacity, including durable partnerships, research networking, and evidence that can inform policy and health system decision-making.

What types of organizations are eligible to apply?

Eligibility is broad and includes many organization types commonly able to hold NIH awards, including state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private higher education institutions; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and an "other" category.

Are non-U.S. (foreign) organizations eligible to apply?

Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).

Are minority-serving and community-based institutions included in eligibility?

Yes. The announcement explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, U.S. territories or possessions, and regional organizations, among others.

Are federal agencies eligible applicants?

Yes. Eligible applicants explicitly include eligible federal agencies.

What is the overall purpose of using an R21 for this topic area?

This FOA is positioned as a launchpad for early, high-potential ideas. It supports preliminary work that can produce feasibility data, proof-of-concept findings, and partnerships needed to build longer-term programs addressing brain and nervous system disorders in LMIC contexts.

What federal activity area is this grant associated with?

The opportunity is categorized under the broad federal activity area of environment, health, income security, and social services.

What assistance listing (CFDA) numbers are associated with this FOA?

The FOA record associates the following assistance listing numbers: 93.113, 93.173, 93.242, 93.853, 93.865, 93.866, 93.867, and 93.989, reflecting involvement across multiple NIH institutes and programs.

What were the key dates noted in the opportunity record?

The record notes a creation date of 2021-09-13 and an original closing date of 2023-12-11.

Should applicants rely on the dates listed here as the current deadline?

No. The information provided notes an original closing date and also indicates that prospective applicants typically confirm the current status, due dates, and any reissued versions through NIH and grants.gov postings, since NIH opportunities can recur in cycles or be updated.

Is the FOA limited to one type of research approach (basic vs. clinical vs. implementation)?

No. The scope is broad and can include basic/mechanistic research, clinical research, public health research, and implementation research, as long as it aligns with the nervous system and lifespan focus and maintains strong global/LMIC relevance.

What kinds of real-world settings does the FOA emphasize?

The FOA emphasizes practical approaches that fit real-world LMIC settings, where research infrastructure and funding may be limited and where scalable, context-appropriate prevention, diagnostic, treatment, and implementation strategies are especially important.

What is the expected "payoff" described for this FOA?

The expected payoff includes both scientific advances and strengthened LMIC research capacity, along with more actionable pathways toward prevention, diagnosis, treatment, and implementation strategies that can work at scale in diverse global settings.